Adjust the research and development strategy Lingbei or will lay off 160 people!

On June 9th Lundbeck announced plans to change and optimize its research and development (R-D) organization to enhance the company's ability to strengthen and advance its product line at all stages of neuroscience, potentially resulting in about 130-160 job cuts at its research and development centerThe research and development center at its Danish headquarters will see about 100 jobs will be created, with the rest likely to come from the U.Sresearch and development centerLingbei has two major research and development centers worldwide, namely Denmark and the United Statesis understood to be part of Lingbei's "expansion and investment growth strategy", which aims to expand the company's operating space and rebuild its potential pipeline of new drugs for brain diseases, including focusing Lingbei's research and development efforts on the most promising areas of scientific research, as well as the company's professional biological platformLingbei's product line covers ailments such as Alzheimer's disease, depression, migraines, Parkinson's, schizophrenia, and the most advanced drugs currently being developed are CGRP antibodies Eptinezumab (Vyepti) and Brexpipleole (Rexulti)Vyepti was approved by the U.SFDA in February to prevent migraines and is the first intravenous doseRexulti was listed in 2015 for the treatment of schizophrenia and later approved for complementary treatment for severe inhibition, and is currently undergoing Phase 2-3 clinical studies on Alzheimer's disorder, post-traumatic stress disorder, and borderline personality disorder's $2 billion acquisition of Alder Bio Pharmaceuticals in 2019, primarily in order to secure Vyepti's interest, and the growing market for migraine control, the drug may not generate high salesDue to the impact of the COVID-19 pandemic, Vyepti had to be used under the management of a doctor, making this year's sales more difficult to meet expectationsWith most of Lingbei's sales coming from earlier development and marketable psychotropic drugs, the company urgently needs a rich pipeline pipeline in the future to sustain its continued development of its slow-moving brain disease treatment productsover the past few years, Lingbei has experienced a series of clinical failures, including two first-in-class candidatedrugs that have entered Phase 2a clinical trials - the metabolic glutamate receptor 4 (mGluR4) regulator foliglurax and the selective sylene hydrolyzed monolriglyglyglycolyt lipase (MGLL) Lu AgAg0646 (ABX-1431), developed for the treatment of motor symptoms and Tourette syndrome in patients with Parkinson's diseaseBoth assets come from what now appears to be a fairly unsuccessful acquisition, involving $1.5bnLingbei is not the only biopharmaceutical company to announce layoffs in the near futureMassachusetts-based AMAG Pharmaceuticals made headlines last month when it said it would cut about 30 percent of its workforce"It is difficult to estimate the severity and duration of the outbreak, and while there are signs of stabilization and confidence in the potential demand for our products, it is impossible to speculate on the speed of recovery that follows and the overall impact on our business," said Scott Myers, President and CEO of AMAG "
it's a smart move to cut costs and rapidly transition to high-value diseases, as the epidemic continues to affect In May, UK-based Orchard Therapeutics also announced a new strategic plan that will change its clinical focus, close the proposed manufacturing facility and cut 25 per cent of its workforce Orchard will no longer focus on the development of stem cell gene therapy for rare diseases, and will focus on drug development for more common diseases, such as Crohn's disease Meanwhile, Orchard will save about $125 million by the end of 2021 through layoffs Reference Source: Lundbeck Plotting Up to 160 R-D Job cuts as it rebuilds pipeline